Skip to main content
Psych Congress  

Pimavanserin Significantly Reduces Risk of Relapse of Dementia-related Psychosis: Results From the Double-Blind Phase of the HARMONY Study

Authors  

Erin Foff, MD, PhD-Executive Director, Clinical Research, ACADIA Pharmaceuticals, Inc; Jeffrey Cummings, MD, ScD-Director, Department of Brain Health, UNLV; Cleveland Clinic Luo Ruvo Center for Brain Health, Las Vegas, NV, USA; Maria-Eugenia Soto-Martin, MD-Professor, Geriatric Medicine, Gerontopole Alzheimer Clinical & Research Center, University Hospital of Toulouse; Pierre Tariot, MD-Director, Banner Alzheimer’s Institute and University of Arizona College of Medicine; Bradley McEvoy, DrPH, MSc-Associate Director, Biostatistics, ACADIA Pharmaceuticals, Inc; Srdjan Stankovic, MD, MSPH-President, Head of R&D, ACADIA Pharmaceuticals, Inc

Sponsor  
ACADIA Pharmaceuticals, Inc.

Patients with dementia often experience dementia-related psychosis (DRP), which is associated with adverse outcomes and has no approved therapy in the US. Pimavanserin is a selective serotonin inverse agonist/antagonist at 5-HT2A receptors approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. We studied pimavanserin use for treating hallucinations and delusion in patients with DRP.

HARMONY was a randomized, placebo-controlled, phase 3 relapse-prevention study. Patients with moderate-to-severe psychosis associated with Alzheimer’s disease dementia, Parkinson's disease dementia, dementia with Lewy bodies, frontotemporal dementia, or vascular dementia were eligible to enroll and received open-label (OL) pimavanserin for 12 weeks. Patients with a sustained response at weeks 8 and 12 were randomized 1:1 to continue pimavanserin or receive placebo for up to 26 weeks in the double-blind (DB) period. The primary endpoint was time from randomization to relapse of DRP.

392 patients enrolled. 217 (61.8%) eligible patients experienced a sustained response and were randomized. The study stopped early for superior efficacy when a prespecified interim analysis revealed >2.8-fold reduction in relapse risk with pimavanserin (hazard ratio: 0.353; 95% CI: 0.172, 0.727; 1-sided P=0.0023). Adverse event rates were low and balanced (OL: 36.2%; DB: 41.0% pimavanserin, 36.6% placebo). No negative trends for worsening in cognition (Mini-Mental State Examination) or motor function (Extrapyramidal Symptoms Rating Scale-A) were observed.

The HARMONY study demonstrated a robust decrease in hallucinations and delusions and significant maintenance of efficacy with pimavanserin treatment in DRP. Pimavanserin was well tolerated by this elderly population over the study duration.

Back to Top